<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01223235</url>
  </required_header>
  <id_info>
    <org_study_id>10-099</org_study_id>
    <nct_id>NCT01223235</nct_id>
  </id_info>
  <brief_title>Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab</brief_title>
  <official_title>A PILOT STUDY OF A POLYVALENT VACCINE-KLH CONJUGATE + OPT-821 GIVEN IN COMBINATION WITH BEVACIZUMAB IN PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN SECOND OR GREATER COMPLETE OR PARTIAL CLINICAL REMISSION</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The immune system of the body has the ability to fight and eliminate infections and cancers.&#xD;
      Immune treatments, such as in this study, seek to teach the immune system to find and destroy&#xD;
      cancer cells. The purpose of this study is to test whether it is safe to treat the cancer&#xD;
      with a vaccine and another drug called bevacizumab (also known as Avastin).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>1 year</time_frame>
    <description>Toxicities evaluated by CTCAE version 4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Met the Immunogenicity Criteria (&gt;/=3 Antigens) of the Vaccine</measure>
    <time_frame>1 year</time_frame>
    <description>when given in the presence of bevacizumab&#xD;
Patients must have IgM titer &gt;1:80, or a fourfold increase in prevailing antibody titer if present at baseline. Twenty-one patients would be accrued, and if &gt;8 of 21 patients should meet these criteria for three or more antigens based on the immune response criteria, the study would be considered positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival as Assessed By Multiplex Biomarker Panel of Angiogenesis Markers</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Progression is defined as at least a 20% increase in the sum of diameters of target lesions. The sum must also demonstrate an absolute increase of at least 5mm.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Fallopian Tubes Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>bevacizumab &amp; polyvalent vaccine-KLH conjugate + OPT-821</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single institution, open label, pilot study of bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821</intervention_name>
    <description>A maximum of 6 doses of the polyvalent-KLH vaccine and OPT-821 will be administered to each patient as per the schedule. Bevacizumab will be administered once every two weeks until week 11 and then once every three weeks according to the schedule. When the 6 vaccinations of the polyvalent-KLH vaccine +OPT821 are completed, patients may still continue to receive bevacizumab on the once every three week schedule.</description>
    <arm_group_label>bevacizumab &amp; polyvalent vaccine-KLH conjugate + OPT-821</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically documented epithelial carcinoma arising in the ovary, fallopian tube or&#xD;
             peritoneum.&#xD;
&#xD;
          -  Patients who have received cytoreductive surgery and chemotherapy with at least one&#xD;
             platinum based chemotherapy regimen. Patients who received neoadjuvant chemotherapy&#xD;
             are eligible.&#xD;
&#xD;
          -  Patients with relapsed ovarian, fallopian tube or primary peritoneal cancer who have&#xD;
             now completed chemotherapy and/or surgery for recurrent disease. Eligible patients are&#xD;
             those who would be appropriate to enter a period of observation if standard management&#xD;
             were considered.&#xD;
&#xD;
          -  Patients who have asymptomatic residual measurable disease on CT scan or be in&#xD;
             complete clinical remission. Patients may have an elevated CA-125. (Complete clinical&#xD;
             remission is defined as serum CA-125 ≤ 35 IU/ml, negative physical examination and&#xD;
             without objective evidence of disease by computed tomography (CT) of the abdomen and&#xD;
             pelvis.)&#xD;
&#xD;
          -  Adequate hematologic, coagulation, renal and hepatic function.&#xD;
&#xD;
          -  ANC &gt; = to 1,000 cells/mm3; platelets &gt; or = 100,000 cells/mm3&#xD;
&#xD;
          -  PT such that international normalized ratio (INR) is &lt; 1.5 (or an in-range INR,&#xD;
             usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin)&#xD;
             Serum creatinine &lt; or = to 1.5 mg/dl&#xD;
&#xD;
          -  Bilirubin, SGOT, Alk Phos &lt; 2.5x upper limit normal&#xD;
&#xD;
          -  Urine protein : creatinine (UPC) ratio must be &lt; 1 . If UPC ratio &gt; 1, collection of&#xD;
             24-hour urine measurement of urine protein is recommended as part of the patient's&#xD;
             medical management off-study.&#xD;
&#xD;
          -  Karnofsky performance status &gt; 70%&#xD;
&#xD;
          -  Expected survival of at least 4 months&#xD;
&#xD;
          -  Age ≥ 18 years. This protocol does not include children because the number of children&#xD;
             with cancer is limited, and because a nationwide pediatric cancer research network&#xD;
             already accesses the majority. Furthermore, the incidence of ovarian, fallopian tube,&#xD;
             or peritoneal cancer in children is extremely infrequent.&#xD;
&#xD;
          -  Patients who are ≥ 4 weeks from completion of prior cytotoxic chemotherapy. Prior&#xD;
             bevacizumab and/or immunotherapy treatment are permitted&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to comply with study and/or follow-up procedures&#xD;
&#xD;
          -  Current or recent (within 4 weeks of the first infusion of this study) participation&#xD;
             in another experimental drug study.&#xD;
&#xD;
          -  Active malignancy, other than superficial basal cell and superficial squamous (skin)&#xD;
             cell, or carcinoma in situ of the cervix within last five years&#xD;
&#xD;
          -  Patients must have undergone standard cytoreductive surgery as part of primary&#xD;
             treatment to be eligible for this study and therefore are not of childbearing&#xD;
             potential.Nursing mothers are excluded.&#xD;
&#xD;
          -  Inadequately controlled hypertension (defined as systolic blood pressure &gt;150 mmHg&#xD;
             and/or diastolic blood pressure &gt; 90 mmHg)&#xD;
&#xD;
          -  Prior history of hypertensive crisis or hypertensive encephalopathy&#xD;
&#xD;
          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure (see&#xD;
             Appendix C)&#xD;
&#xD;
          -  History of myocardial infarction or unstable angina within 6 months prior to Day 1&#xD;
&#xD;
          -  History of stroke or transient ischemic attack within 6 months prior to Day 1&#xD;
&#xD;
          -  Known CNS disease, except for treated brain metastasis&#xD;
&#xD;
          -  Treated brain metastases are defined as having no evidence of progression or&#xD;
             hemorrhage after treatment and no ongoing requirement for dexamethasone, as&#xD;
             ascertained by clinical examination and brain imaging (MRI or CT) during the screening&#xD;
             period. Anticonvulsants (stable dose) are allowed. Treatment for brain metastases may&#xD;
             include whole brain radiotherapy (WBRT), radiosurgery (RS; Gamma Knife, LINAC, or&#xD;
             equivalent) or a combination as deemed appropriate by the treating physician. Patients&#xD;
             with CNS metastases treated by neurosurgical resection or brain biopsy performed&#xD;
             within 3 months prior to Day 1 will be excluded&#xD;
&#xD;
          -  Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or&#xD;
             recent peripheral arterial thrombosis) within 6 months prior to Day 1&#xD;
&#xD;
          -  History of hemoptysis (≥ 1/2 teaspoon of bright red blood per episode) within 1 month&#xD;
             prior to Day 1&#xD;
&#xD;
          -  Evidence of bleeding diathesis or significant coagulopathy (in the absence of&#xD;
             therapeutic anticoagulation) or tumor involving major vessels.&#xD;
&#xD;
          -  Major surgical procedure such as laparotomy, open biopsy, or significant traumatic&#xD;
             injury within 28 days prior to Day 1 or anticipation of need for major surgical&#xD;
             procedure during the course of the study&#xD;
&#xD;
          -  Core biopsy or other minor surgical procedure, excluding placement of a vascular&#xD;
             access device, within 7 days prior to Day 1&#xD;
&#xD;
          -  History of abdominal fistula or gastrointestinal perforation within 6 months prior to&#xD;
             Day&#xD;
&#xD;
          -  Patients with clinical symptoms or signs of GI obstruction who require parenteral&#xD;
             hydration, parenteral nutrition, or tube feeding&#xD;
&#xD;
          -  Patients with evidence of abdominal free air not explained by paracentesis or recent&#xD;
             surgical procedure&#xD;
&#xD;
          -  Serious, non-healing wound, active ulcer, or untreated bone fracture&#xD;
&#xD;
          -  Known hypersensitivity to any component of bevacizumab&#xD;
&#xD;
          -  Allergy to seafood&#xD;
&#xD;
          -  Active autoimmune disease (i.e. rheumatoid arthritis, ulcerative colitis etc); or&#xD;
             immune deficiency (HIV, hypogammaglobulinemia); or known active infections with&#xD;
             Hepatitis B or Hepatitis C; or those receiving immunosuppressive drugs (such as&#xD;
             chronic systemic corticosteroids or cyclosporin, etc); or those receiving chronic&#xD;
             antiinflammatory drugs (intermittent use of anti-inflammatory drugs is permitted).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Sabbatini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan-Kettering Cancer Center</description>
  </link>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>October 14, 2010</study_first_submitted>
  <study_first_submitted_qc>October 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2010</study_first_posted>
  <results_first_submitted>March 16, 2018</results_first_submitted>
  <results_first_submitted_qc>April 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 14, 2018</results_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FALLOPIAN TUBE</keyword>
  <keyword>OVARY</keyword>
  <keyword>PERITONEUM</keyword>
  <keyword>BEVACIZUMAB (AVASTIN)</keyword>
  <keyword>GLOBO H-KLH CONJUGATE</keyword>
  <keyword>MUC-1 KLH</keyword>
  <keyword>OPT-821</keyword>
  <keyword>TF (C) - KLH</keyword>
  <keyword>TN(C)-KLH</keyword>
  <keyword>10-099</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 12, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT01223235/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bevacizumab &amp; Polyvalent Vaccine-KLH Conjugate + OPT-821</title>
          <description>This is a single institution, open label, pilot study of bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bevacizumab &amp; Polyvalent Vaccine-KLH Conjugate + OPT-821</title>
          <description>This is a single institution, open label, pilot study of bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="49" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Toxicities evaluated by CTCAE version 4.0</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab &amp; Polyvalent Vaccine-KLH Conjugate + OPT-821</title>
            <description>This is a single institution, open label, pilot study of bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Toxicities evaluated by CTCAE version 4.0</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Met the Immunogenicity Criteria (&gt;/=3 Antigens) of the Vaccine</title>
        <description>when given in the presence of bevacizumab&#xD;
Patients must have IgM titer &gt;1:80, or a fourfold increase in prevailing antibody titer if present at baseline. Twenty-one patients would be accrued, and if &gt;8 of 21 patients should meet these criteria for three or more antigens based on the immune response criteria, the study would be considered positive.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab &amp; Polyvalent Vaccine-KLH Conjugate + OPT-821</title>
            <description>This is a single institution, open label, pilot study of bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Met the Immunogenicity Criteria (&gt;/=3 Antigens) of the Vaccine</title>
          <description>when given in the presence of bevacizumab&#xD;
Patients must have IgM titer &gt;1:80, or a fourfold increase in prevailing antibody titer if present at baseline. Twenty-one patients would be accrued, and if &gt;8 of 21 patients should meet these criteria for three or more antigens based on the immune response criteria, the study would be considered positive.</description>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival as Assessed By Multiplex Biomarker Panel of Angiogenesis Markers</title>
        <description>Progression is defined as at least a 20% increase in the sum of diameters of target lesions. The sum must also demonstrate an absolute increase of at least 5mm.</description>
        <time_frame>Up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab &amp; Polyvalent Vaccine-KLH Conjugate + OPT-821</title>
            <description>This is a single institution, open label, pilot study of bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival as Assessed By Multiplex Biomarker Panel of Angiogenesis Markers</title>
          <description>Progression is defined as at least a 20% increase in the sum of diameters of target lesions. The sum must also demonstrate an absolute increase of at least 5mm.</description>
          <units>months (Progression Free Survival)</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="10" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Until time to treatment failure, up to 20 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab &amp; Polyvalent Vaccine-KLH Conjugate + OPT-821</title>
          <description>This is a single institution, open label, pilot study of bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Serum amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Paul Sabbatini, MD</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>212-639-4016</phone>
      <email>sabbatip@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

